| Outcome Measures: |
Primary: Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo, Week 0, 4 | Secondary: Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo, Weeks 0 and 4|Change from baseline in fasting plasma glucose, Weeks 0, 2, 4 and 6|Change from baseline in Glycosylated Hemoglobin (HbA1c), Weeks 0, 4 and 6|Change from baseline in fasting total cholesterol, Weeks 0, 4 and 6|Change from baseline in glucose AUC(0-5) during mixed meal tolerance test (MMTT), Weeks 0, 4 and 6|Change from baseline in insulin AUC(0-5) during mixed meal tolerance test (MMTT), Weeks 0, 4 and 6|Change from baseline in C-peptide AUC(0-5) during mixed meal tolerance test (MMTT), Weeks 0, 4 and 6|Change from baseline in ratio of AUC(0-5) insulin to AUC(0-5) glucose during the MMTT, Weeks 0, 4 and 6|Change from baseline in ratio of AUC (0-5) C-peptide to AUC(0-5) glucose during the MMTT, Weeks 0, 4 and 6|Change from baseline in homeostatic model assessment for insulin resistance (HOMA IR), Weeks 0, 4 and 6|Change from baseline in homeostatic model assessment for β-cell function (HOMA B), Weeks 0, 4 and 6|Change from baseline in low density lipoprotein cholesterol (LDL-C), Weeks 0, 4 and 6|Plasma concentrations for PF-05175157, Weeks 2, 4 and 6|Percent change from baseline in body weight, Weeks 0, 4 and 6|Change from baseline in high density lipoprotein cholesterol (HDL-C), Weeks 0, 4 and 6|Change from baseline in triglycerides, Weeks 0, 4 and 6|Change from baseline in non-HDL cholesterol, Weeks 0, 4 and 6|Change from baseline in very low density lipoprotein (VLDL), Weeks 0, 4 and 6
|
